- Ticker
- ABCL
- Price
- 11.18
- Stock movement up
- +0.17 (1.54%)
- Company name
- Abcellera Biologics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.20B
- Ent value
- 3.13B
- Price/Sales
- 5.30
- Price/Book
- 2.56
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 12.88
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 20.47%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2023-02-03
DIVIDENDS
ABCL does not pay dividends
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 12.88 |
| Price to OCF | 13.92 |
| Price to FCF | 19.99 |
| Price to EBITDA | 8.47 |
| EV to EBITDA | 8.28 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.30 |
| Price to Book | 2.56 |
| EV to Sales | 5.19 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 286.10M |
| EPS (TTM) | 0.79 |
| FCF per share (TTM) | 0.51 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 603.21M |
| Gross profit (TTM) | 516.44M |
| Operating income (TTM) | 335.84M |
| Net income (TTM) | 248.36M |
| EPS (TTM) | 0.79 |
| EPS (1y forward) | -0.45 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 85.61% |
| Operating margin (TTM) | 55.68% |
| Profit margin (TTM) | 41.17% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 371.97M |
| Net receivables | 105.96M |
| Total current assets | 1.05B |
| Goodwill | 47.81M |
| Intangible assets | 142.55M |
| Property, plant and equipment | 0.00 |
| Total assets | 1.55B |
| Accounts payable | 9.32M |
| Short/Current long term debt | 76.11M |
| Total current liabilities | 106.05M |
| Total liabilities | 302.24M |
| Shareholder's equity | 1.25B |
| Net tangible assets | 1.06B |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 229.74M |
| Capital expenditures (TTM) | 69.76M |
| Free cash flow (TTM) | 159.98M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 19.87% |
| Return on Assets | 16.00% |
| Return on Invested Capital | 19.79% |
| Cash Return on Invested Capital | 12.75% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 10.83 |
| Daily high | 11.38 |
| Daily low | 10.73 |
| Daily Volume | 1.24M |
| All-time high | 53.20 |
| 1y analyst estimate | 29.20 |
| Beta | -0.24 |
| EPS (TTM) | 0.79 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 21 Feb 2023 |
Downside potential
Loading...
Downside potential data
| ABCL | S&P500 | |
| Current price drop from All-time high | -78.98% | -13.68% |
| Highest price drop | -89.25% | -56.47% |
| Date of highest drop | 11 May 2022 | 9 Mar 2009 |
| Avg drop from high | -66.14% | -11.49% |
| Avg time to new high | 108 days | 13 days |
| Max time to new high | 507 days | 1805 days |
COMPANY DETAILS
Marketcap
3.20B
Marketcap category
Mid-cap
Description
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Employees
475
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
VANCOUVER, British Columbia, February 01, 2023--AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023
February 1, 2023
VANCOUVER, British Columbia, January 24, 2023--AbCellera to Report Full Year 2022 Financial Results on February 21, 2023
January 24, 2023
Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately.
January 24, 2023
AbCellera Biologics saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 77 to 81. When looking for the best stocks to buy and watch, keep a close on eye on relative...
January 23, 2023
VANCOUVER, British Columbia, January 20, 2023--AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent
January 20, 2023
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
January 19, 2023
Pliant Therapeutics, Inc. (PLRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in ...
January 12, 2023
It is hard to get excited after looking at AbCellera Biologics' (NASDAQ:ABCL) recent performance, when its stock has...
January 5, 2023
VANCOUVER, British Columbia, January 04, 2023--AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023
January 4, 2023
Those following along with AbCellera Biologics Inc. ( NASDAQ:ABCL ) will no doubt be intrigued by the recent purchase...
December 22, 2022
Next page